Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results

 

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2020. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

 

  2020 Highlights  

 

Financials

 
  • Revenues were $199,519, an increase of $152,058 or 320% over prior year.
  •  
  • Gross margin was $81,690 or 41% compared to $26,918 or 57% in prior year.
  •  
  • Adjusted EBITDA 1 was $16,837 compared to $2,827 in prior year.
  •  
  • Interest income generated of $14,322 a decrease of $9,220 or 39% over prior year.
  •  
  • Gain from strategic fund investments of $46,733, of which $16,644 was realized.
  •  
  • Adjusted earnings 1 of $28,713, an increase of $2,714 or 10% over prior year.
  •  
  • Net income was $31,760 compared to net income of $18,033 in prior year.
  •  

Corporate Developments

 
  • Promoted Arvind Utchanah from VP Finance to CFO.
  •  
  • Appointed Janice Murray and Nicolás Sujoy on the Board of Directors.
  •  
  • Disposed of the shares of Medison Biotech (1995) Ltd. for a cash consideration of $77,000 and recorded a gain of $2,948.
  •  
  • Purchased 5,748,716 common shares at an average price of $6.40 per share through a Normal Course Issuer Bid ("NCIB").
  •  
  • Completed the tender offer process for an aggregate purchase price of $170,855 and achieved 99.9% ownership of Biotoscana Investments S.A. ("GBT").
  •  

Products

 
  • Launched Cresemba ® , indicated for the treatment of invasive aspergillosis and invasive mucormycosis, in Brazil.
  •  
  • Launched Karfib ® , indicated for relapsed or refractory multiple myeloma, in Argentina.
  •  
  • Received regulatory approval from Health Canada for Ibsrela™ for the treatment of Irritable Bowel Syndrome with Constipation ("IBS-C").
  •  
  • Obtained the exclusive Canadian commercial rights of Trelstar ® , approved for the treatment of advanced prostate cancer.
  •  
  • Obtained regulatory approval for Lenvima ® and Halaven ® in Ecuador.
  •  
  • Received regulatory approval from Health Canada for Imvexxy™ and Bijuva™.
  •  
  • Submitted a supplement to a New Drug Submission ("NDS") of Nerlynx ® for HER2-positive metastatic breast cancer.
  •  
  • Signed a new exclusive distribution agreement with Gilead for the continued commercialization of AmBisome ® in Brazil, effective January 1, 2021.
  •  

Strategic Investments

 
  • Disposed of 111,355 common shares of Profound Medical Inc. for total proceeds of $1,825.
  •  
  • Received US$5,000 for the full repayment of the strategic loan issued to Triumvira Immunologics Inc.
  •  
  • Amended strategic loan issued to Synergy CHC Corp. and loaned an additional US$2,500.
  •  
  • Received distributions of $29,128 from strategic fund investments and realized a gain of $16,644.
  •  

Key Subsequent Event

 
  • Purchased an additional 2,895,456 common shares at an average price of $5.25 per share through the NCIB.
  •  
  • Disposed of 315,600 common shares of Medexus Pharmaceuticals Inc. for total proceeds of $2,624.
  •  
  • Announced the Canadian commercial launch of Ibsrela™ for the treatment of IBS-C.
  •  

"The past year was a transformative year for Knight with the completion of the acquisition of GBT. Despite the challenges due to COVID-19, we continue to progress on integration, while advancing on our product portfolio in both Canada and Latin America. We have received regulatory approvals from Health Canada for Ibsrela™, Imvexxy™ and Bijuva ® and received regulatory approvals for Lenvima ® and Halaven ® in Ecuador. We continue to focus on our mission to acquire, in-license, develop and commercialize innovative medicines and high-quality treatments to improve the health of patients in Latin America and Canada," said Samira Sakhia, President and Chief Operating Officer of Knight Therapeutics Inc.

 

___________________
1   Adjusted   earnings   and adjusted EBITDA   are   not defined term   s   under IFRS, refer to   the definition   s   below for additional details   .  

 

  
 

 

  SELECT FINANCIAL RESULTS & BALANCE SHEET ITEMS  
[In thousands of Canadian dollars]

 
                                                                                                                                                                                                                                                                                            
     Change      Change  
   Q4-20    Q4-19    $   1     %   2    YTD-20   YTD-19   $   1     %   2  
         
Revenues   55,191    37,271   17,920   48 %   199,519    47,461   152,058   320 %
Gross margin   20,060    18,399   1,661   9 %   81,690    26,918   54,772   203 %
Selling and marketing   8,657    4,448   (4,209 ) 95 %   35,585    7,789   (27,796 ) 357 %
General and administrative   11,421    12,121   700   6 %   38,845    24,460   (14,385 ) 59 %
Research and development   3,690    1,411   (2,279 ) 162 %   11,725    3,913   (7,812 ) 200 %
Amortization of intangible assets   7,989    2,140   (5,849 ) 273 %   25,535    3,413   (22,122 ) 648 %
Impairment of intangible assets   656    4,226   3,570   84 %   656    4,226   3,570   84 %
  Operating loss    (12,353    )   (5,947 ) (6,406 ) 108 %   (30,656    )   (16,883 ) (13,773 ) 82 %
Interest income   (2,807    )   (5,434 ) (2,627 ) 48 %   (14,322    )   (23,542 ) (9,220 ) 39 %
Interest expense   328    370   42   11 %   3,398    370   (3,028 ) 818 %
Foreign exchange loss (gain)   4,490    (1,926 ) (6,416 ) N/A    14,156    1,389   (12,767 ) 919 %
  Net income (loss)    8,233    (3,153 ) 11,386   N/A    31,760    18,033   13,727   76 %
Basic net earnings (loss) per share   0.063    (0.049 ) 0.112   N/A    0.319    0.104   0.215   207 %
  Adjusted EBITDA   3    1,771    6,180   (4,409 ) 71 %   16,837    2,827   14,010   496 %
  Adjusted earnings   3    4,174    11,244   (7,070 ) 63 %   28,713    25,999   2,714   10 %
 

 

 
      
   1     A positive variance represents a positive impact to net income and a negative variance represents a negative impact to net income  
   2     Percentage change is presented in absolute values  
   3     Adjusted EBITDA and adjusted earnings are non-IFRS measures, refer to section "Adjusted EBITDA and Adjusted Earnings" for additional details  
 

 

 
                                                        
     Change  
   12-31-20    12-31-19    $    %   1  
     
Cash, cash equivalents, restricted cash and marketable securities   392,225   536,182 (143,957 ) 27 %
Trade and other receivables   75,089   108,182 (33,093 ) 31 %
Inventory   56,505   70,870 (14,365 ) 20 %
Financial assets   193,955   159,151 34,804   22 %
Accounts payable, accrued and other liabilities   46,119   96,156 (50,037 ) 52 %
Bank loans   51,770   55,579 (3,809 ) 7 %
 

 

 
    
  1    Percentage change is presented in absolute values  
  
 

  Revenue: For the quarter ended December 31, 2020, revenues increased by $17,920 or 48% over prior year driven primarily by full quarter consolidation of GBT's financial results compared to one moth in 2019. For the year ended December 31, 2020, revenues increased by $152,058 or 320% as compared to the same period in the prior year driven by the consolidation of GBT's financial results.

 

  Gross margin: For the quarter ended December 31 , 2020, the gross margin decreased from 49% to 36% compared to the same period in the prior year due to the consolidation of GBT's results, change in product mix and an inventory write-off of $3,249 as a result of the impact of COVID-19 on certain new product launches. The gross margin would have been 40%, an increase of 4%, from 36% after excluding the adjustment of hyperinflation accounting in accordance with IAS 29.

 

For the year ended December 31 , 2020, the gross margin decreased from 57% to 41% compared to the same period in the prior year due to consolidation of GBT's results and an inventory write-off of $10,046 as a result of the impact of COVID-19 on certain new product launches. The gross margin would have been 44%, an increase of 3%, from 41% after excluding the adjustment of hyperinflation accounting in accordance with IAS 29.

 

  Selling and marketing: The increase of $4,209 for the quarter and $27,796 for the twelve-month period ended December 31, 2020 compared to the same prior year periods is primarily driven by the consolidation of GBT's results.

 

  General and administrative: For the year ended December 31, 2020, the general and administrative expenses increased by $14,385 or 59% as compared to the same period in prior year driven by the consolidation of GBT's expenses of $22,052 partially offset by a decrease in one time costs related to the GBT acquisition and the public proxy battle.

 

  Research and development: For the quarter and year ended December 31, 2020, research and development expenses increased by $2,279 or 162% and $7,812 or 200% compared to the same prior year periods. The increase is driven by the consolidation of GBT's financial results and the continued investment in the Canadian product launches.

 

  Amortization of intangible assets: Increase due to the amortization of the definite-life intangible assets acquired in the GBT acquisition.

 

  Interest income: Interest income is the sum of interest income on financial instruments measured at amortized cost and other interest income. For the quarter, interest income was $2,807, a decrease of 48% or $2,627 compared to the same period prior year. For the year, interest income was $14,322 a decrease of 39% or $9,220 compared to the same period in prior year. The decrease in both instances is due to lower interest rates, average cash, marketable securities and strategic loan balances.

 

  Interest expense: The consolidation of GBT's financial results accounted for $3,131 of incremental interest expense for the year ended December 31, 2020 mainly related to interest on its bank loans.

 

  Net income or loss: For the quarter ended December 31, 2020, net income was $8,233 an increase of $11,386 compared to the same period last year. The variance mainly resulted from the above-mentioned items as well as a net gain on the revaluation of financial assets measured at fair value through profit or loss of $25,418 (Q4-19 gain of $1,065).

 

For the year net income was $31,760 an increase of $13,727 compared to the same period last year. The variance mainly resulted from the above-mentioned items as well as (i) net gain on the revaluation of financial assets measured at fair value through profit or loss of $48,060 (Q4-19 gain of $20,714), (ii) net gain on mandatory tender offer ("MTO") liability of $12,072 mainly driven by the public shareholders of GBT tendering their shares using the Alternative Offer Price at BRL 10.40 per share, (iii) loss on hyperinflation of $1,444 due to net monetary positions under hyperinflation accounting.

 

  Adjusted EBITDA : For the three-month period ended December 31, 2020, adjusted EBITDA was $1,771, a decrease of $4,409 or 71% compared to the same period last year. The variance is mainly explained by an inventory write-off of $3,249 in the fourth quarter of 2020. For the twelve-month period ended December 31, 2020, adjusted EBITDA was $16,837, an increase of $14,010 or 496% compared to the same period last year. For the twelve-month period, the variance is mainly due to the consolidation of GBT's adjusted EBITDA.

 

  Adjusted Earnings : For the three-month period ended December 31, 2020, adjusted earnings were $4,174 a decrease of $7,070 or 63% compared to the same period last year. For the twelve months period ended December 31, 2020, adjusted earnings were $28,713 an increase of $2,714 or 10% as compared to the same period last year. The variance is mainly explained by the incremental adjusted earnings of the GBT acquisition offset by a decline in interest income.

 

  Cash, cash equivalents, restricted cash and marketable securities : As at December 31, 2020, Knight had $392,225 in cash, cash equivalents and marketable securities, a decrease of $143,957 or 27% as compared to December 31, 2019. The variance is primarily due to cash outflows related to the acquisition of the outstanding BDRs of GBT, shares repurchased through NCIB and changes in working capital partially offset by Medison settlement.

 

  Financial assets: The increase of $34,804 for the year ended December 31, 2020 compared to the prior year is due to the following: (i) increase of $2,537 attributable to loans and receivables as a result of additional loans issued partially offset by loss on foreign exchange revaluations and changes in fair value (ii) decrease in equity investments, warrants and derivatives of $3,408 due to disposal and revaluation, and (iii) increase of $35,675 attributable to fund investments.

 

  Bank Loans: As at December 31, 2020, bank loans were at $51,770, a decrease of $3,809 mainly due to loan repayment of $14,714 and a further decrease of $14,178 due to the foreign exchange revaluation, partially offset by additional loans of $24,581 issued in March and December 2020. Subsequent to the year end, loan balance was reduced by $10,111.

 

 

 

  Product Updates  

 

On January 8, 2020, Knight announced that the Company entered into an agreement with Debiopharm for the Canadian commercial rights of Trelstar® (triptorelin), for the treatment of advanced prostate cancer and the management and relief of chronic pain associated with endometriosis. On April 20, 2020, the Company announced that it took over commercial activities from Debiopharm's previous partner, Allergan, and is commercializing Trelstar ® in Canada. According to IQVIA data, Trelstar® sales in Canada were $1,824 for the year ended December 31, 2020 (2019: $2,179).

 

In the first quarter of 2020 the Company launched Cresemba ® (isavuconazonium sulfate) in Brazil which was licensed from Basilea Pharmaceuticals for the treatment of invasive aspergillosis and invasive mucormycosis. Knight also launched Karfib ® (carfilzomib) in Argentina, which is indicated for relapsed or refractory myeloma.

 

During the year, the Company received a regulatory approval from Health Canada for Ibsrela™ (tenapenor) for the treatment of IBS-C, which was launched subsequent to the year end. Knight also received a regulatory approval for Imvexxy™ (estradiol vaginal inserts) indicated for the treatment of moderate-to-severe dyspareunia and Bijuva™ (estradiol and progesterone) used for the treatment of moderate-to-severe vasomotor symptoms. Knight also submitted a supplement to a NDS of Nerlynx ® (neratinib) for HER2-positive metastatic breast cancer. Moreover, the Company obtained a regulatory approval for Lenvima ® (lenvatinib) and Halaven ® (eribulin mesylate) in Ecuador.

 

On October 26, 2020, Knight signed a new exclusive distribution agreement with Gilead Sciences Inc. for the commercialization of AmBisome ® (liposomal amphotericin B) in Brazil. The agreement will be effective starting January 1, 2021. This product has been a part of Knight's Brazilian affiliate's portfolio for over twenty years.

 

  NCIB  

 

On July 10, 2020, the Company announced that the Toronto Stock Exchange approved its notice of intention to launch an additional NCIB (‘2020 NCIB"). Under the terms of the 2020 NCIB, Knight may purchase for cancellation up to 10,856,710 common shares of the Company which represented 10% of its public float as at July 6, 2020. The 2020 NCIB commenced on July 14, 2020 and will end on the earlier of July 13, 2021 or when the Company completes its maximum purchases under the 2020 NCIB. Furthermore, Knight entered into an agreement with a broker to facilitate purchases of its common shares under the 2020 NCIB. Under Knight's automatic share purchase plan, the broker may purchase common shares which would ordinarily not be permitted due to regulatory restrictions or self-imposed blackout periods. During the twelve -month period ended December 31, 2020, the Company purchased 944,273 common shares under the 2020 NCIB, for an aggregate cash consideration of $5,522. Subsequent to year end, the Company purchased an additional 2,895,456 common shares, of which 1,605,699 remain to be cancelled, for an aggregate cash consideration of $15,206.

 

  Acquisition of GBT  

 

On July 15, 2020, Knight announced the launch of the tender offer for the acquisition and delisting of the remaining 48.8% Brazilian Depository Receipts ("BDRs") of GBT. The public shareholders had the choice between the following two tender options:

 
  • BRL11.23 per BDR with an amount equivalent to 20% deposited in an escrow account to secure the sellers' indemnification obligations under the purchase agreement for the GBT Transaction, provided that BRL 0.91 of the escrow amount shall be mandatorily paid on or at any time prior to November 29, 2022. The escrow amount will be released equally over a period of three years from closing, net of claims in accordance with the terms and conditions of the Share Purchase Agreement.
  •  
  • BRL10.40 per BDR in cash on the settlement date ("Alternative Offer Price").
  •  

Upon close of the tender offer process, 99.6% of the public shareholders tendered their BDRs through the Alternative Offer Price. The Company paid an aggregate purchase price of $170,855 [BRL 537,523] and obtained 99.9% ownership of GBT. On October 23, 2020, the BDR program of GBT was cancelled by the Brazilian Securities and Exchange Commission.

 

 

 

  COVID-19 Update  

 

The recent outbreak of the coronavirus, or COVID-19, which has been declared by the World Health Organization to be a pandemic, has spread across the globe and is impacting worldwide economic activity. Certain countries where the Company has significant operations, have required entities to limit or suspend business operations and have implemented travel restrictions and quarantine measures. Knight is continuing to work to alleviate some of the pressure that the global COVID-19 pandemic has placed on our healthcare systems and ensure that we maintain supply of our medicines to patients. The Company and its employees have transitioned to working remotely, including our field sales and medical teams. The Company has taken steps to establish digital and virtual channels to ensure that physicians and patients continue to receive continued support. Knight is developing return to field or office protocols on a country by country basis. Furthermore, the Company has not faced any inventory shortages and has sufficient liquidity to meet all operating requirements for the foreseeable future. As the date hereof, the outbreak has not had a material impact on the Company's results.

 

 

 

  Conference Call Notice  

 

Knight will host a conference call and audio webcast to discuss its third quarter results today at 8:30 am ET. Knight cordially invites all interested parties to participate in this call.

 

  Date: Thursday, March 25, 2021
Time: 8:30 a.m. ET
Telephone: : Toll Free 877-876-9176 or International 785-424-1670
Webcast:   www.gud-knight.com or Webcast  
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.

 

  Replay: An archived replay will be available for 30 days at https://www.gud-knight.com  

 

 

 

  About Knight Therapeutics Inc.  

 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

 

  Forward-Looking Statement  

 

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

 

  CONTACT INFORMATION:  

 
                        
  Investor Contact:    
Knight Therapeutics Inc.   
Samira Sakhia   Arvind Utchanah
President & Chief Operating Officer   Chief Financial Officer
T: 514.484.4483 ext.122   T. 514.484.4483 ext. 115
F: 514.481.4116   F. 514.481.4116
Email: info@knighttx.com    Email: info@knighttx.com  
Website: www.gud-knight.com    Website: www.gud-knight.com  
 

  
 

 

  IMPACT OF HYPERINFLATION  
[In thousands of Canadian dollars]

 

The Company applies IAS 29, Financial Reporting in Hyperinflation Economies, as the Company's Argentine subsidiaries used the Argentine Peso as their functional currency. IAS 29 requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy be adjusted based on an appropriate general price index to express the effects of inflation. If the Company did not apply IAS 29, the effect on the Company's operating income would be as follows:

 

   Q4-20   

 
                                                                                                                  
   Reported
under IFRS
 
   Excluding impact
of IAS 29
 
   Variance  
    $   1     %   2  
     
Revenues   55,191     56,676    (1,485 ) 3 %
Cost of goods sold   35,131     33,769    (1,362 ) 4 %
  Gross margin    20,060     22,907    (2,847 ) 12 %
  Gross margin (%)    36    %    40    %    
     
  Expenses      
Selling and marketing   8,657     9,287    630   7 %
General and administrative   11,421     11,558    137   1 %
Research and development   3,690     3,784    94   2 %
Amortization of intangible assets   7,989     7,622    (367 ) 5 %
Impairment of intangible assets   656     656     0 %
Operating loss   (12,353    )    (10,000    )   (2,353 ) 24 %
 

 

 
      
   1     A positive variance represents a positive impact to net income due to the application of IAS 29 and a negative variance represents a negative impact to net income due to the application of IAS 29  
   2     Percentage change is presented in absolute values  
  
 

   YTD-20   

 
                                                                                                                  
   Reported
under IFRS
 
   Excluding impact
of IAS 29
 
   Variance  
    $   1     %   2  
     
Revenues   199,519     202,536    (3,017 ) 1 %
Cost of goods sold   117,829     112,561    (5,268 ) 5 %
  Gross margin    81,690     89,975    (8,285 ) 9 %
  Gross margin (%)    41    %    44    %    
     
  Expenses      
Selling and marketing   35,585     36,309    724   2 %
General and administrative   38,845     38,214    (631 ) 2 %
Research and development   11,725     11,958    233   2 %
Amortization of intangible assets   25,535     25,029    (506 ) 2 %
Impairment of intangible assets   656     656     0 %
  Operating Loss    (30,656    )    (22,191    )   (8,465 ) 38 %
 

 

 
      
   1     A positive variance represents a positive impact to net income due to the application of IAS 29 and a negative variance represents a negative impact to net income due to the application of IAS 29  
   2     Percentage change is presented in absolute values  
  
 

  RECONCILIATION TO ADJUSTED EBITDA AND ADJUSTED EARNINGS  
[In thousands of Canadian dollars]

 

  Non-IFRS measure: EBITDA and Adjusted earnings  

 

The Company discloses non-IFRS measures that do not have standardized meanings prescribed by IFRS. The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company's financial performance and in interpreting the effect of the GBT Transaction on the Company. Non-IFRS financial measures do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other companies.

 

  The Company uses the following non-IFRS measures:  

 

  EBITDA: Operating (loss) income adjusted to exclude amortization and impairment of intangible assets, depreciation, PPA accounting adjustments, and the impact of IAS 29 (accounting under hyperinflation) but to include costs related to leases. In addition, EBITDA does not reflect the portion of GBT's adjusted earnings attributable to the non-controlling interests.

 

  Adjusted EBITDA: EBITDA adjusted for acquisition costs and non-recurring expenses

 

  Adjusted earnings: Adjusted EBIDTA adjusted to include interest income earned and interest expenses on bank loans.

 

Adjustments include the following:

 
  • With the adoption of IFRS 16, the lease payments of Knight are not reflected in operating expenses. The IFRS 16 adjustment approximates the cash outflow related to leases of Knight.
  •  
  • Acquisition costs relate to costs incurred on legal, consulting and advisory fees for the acquisition of GBT.
  •  
  • Other non-recurring expenses relate to expenses incurred by Knight that are not due to, and are not expected to occur in, the ordinary course of business. For the quarter and the twelve-month period ended December 31, 2020, Knight recorded one-time costs of $2,603 and $5,383 respectively. The expenses related to restructuring activities including severance to certain employees as part of restructuring and integration of GBT, inventory destruction and bad debt against accounts receivable.
  •  
  • Interest income Includes "Interest income on financial instruments measured at amortized cost" and "Other interest income", primarily from interest earned on loans, cash and cash equivalents, marketable securities and accretion on loans receivable.
  •  
  • Interest expense on bank loans includes GBT's interest expense mainly related to interest on its bank loans
  •  

For the three-month and twelve-month periods ended December 31, 2020, the Company calculated adjusted EBITDA and adjusted earnings as follows:

 
                                                                                                                                            
   Q4-20    Q4-19    YTD-20    YTD-19  
  Operating loss    (12,353    )   (5,947 )   (30,656    )   (16,883 )
Adjustments to operating loss:     
Amortization of intangible assets   7,989    2,140    25,535    3,413  
Impairment of intangible assets   656    4,226    656    4,226  
Depreciation of property, plant and equipment and right-of-use assets   1,624    552    6,540    857  
Lease costs (IFRS 16 adjustment)   (734    )   (336 )   (3,139    )   (564 )
Impact of PPA accounting     (407 )   865    (407 )
Impact of IAS 29   1,986      7,960    
  EBITDA    (832    )   228    7,761    (9,358 )
Acquisition costs     5,542    3,693    8,019  
Other non-recurring expenses   2,603    410    5,383    4,166  
  Adjusted EBITDA    1,771    6,180    16,837    2,827  
Interest income   2,807    5,434    14,322    23,542  
Interest expense on bank loans   (404    )   (370 )   (2,446    )   (370 )
  Adjusted earnings    4,174    11,244    28,713    25,999  
 

 

 
      
   1     A positive variance represents a positive impact to adjusted earnings and a negative variance represents a negative impact to net income  
   2     Percentage change is presented in absolute values  
  
 

  CONSOLIDATED BALANCE SHEETS  
[In thousands of Canadian dollars]

 
                                                                                    
   12-31-20   12-31-19
   
  ASSETS    
  Current    
Cash, cash equivalents and restricted cash   229,592   174,268
Marketable securities   147,316   235,045
Trade receivables   62,515   85,845
Other receivables   12,413   17,622
Inventories   56,505   70,870
Prepaids and deposits   2,214   3,306
Other current financial assets   34,431   26,303
Income taxes receivable   7,115   8,265
  Total current assets    552,101    621,524  
   
Marketable securities   15,317   126,869
Trade receivables   161   4,715
Prepaids and deposits   4,047   4,652
Right-of-use Assets   4,035   6,409
Property, plant and equipment   22,127   22,639
Investment properties   1,539   1,740
Intangible assets   156,547   173,372
Goodwill   77,725   88,262
Other financial assets   159,524   132,848
Deferred income tax assets   2,432   3,991
Other long-term receivables   41,582   41,582
   485,036    607,079  
Assets held for sale   2,539   76,700
  Total assets    1,039,676    1,305,303  
 

 

 

  CONSOLIDATED BALANCE SHEETS (continued)  
[In thousands of Canadian dollars]

 
                                                                                                                  
   12-31-20    12-31-19
   
  LIABILITIES AND EQUITY    
  Current    
Accounts payable and accrued liabilities   44,512    94,406
Lease liabilities   1,875    1,788
Other liabilities   1,291    1,750
Mandatory tender offer liability   184,023
Bank loans   51,770    50,557
Income taxes payable   13,559    15,447
Other balances payable   1,053    2,833
  Total current liabilities    114,060    350,804
   
Accounts payable and accrued liabilities   316   
Lease liabilities   2,543    4,812
Bank loan   5,022
Other balances payable   14,900    1,699
Deferred income tax liabilities   21,616    27,860
  Total liabilities    153,435    390,197
   
  Equity    
Share capital   694,351    723,832
Warrants   117    785
Contributed surplus   18,731    16,463
Accumulated other comprehensive income   (1,503    )   17,405
Retained earnings   174,545    52,246
  Attributable to shareholders of the Company    886,241    810,731
Non-controlling interests   104,375
  Total equity    886,241    915,106
  Total liabilities and equity    1,039,676    1,305,303
 

 

 

  CONSOLIDATED STATEMENTS OF INCOME  
[In thousands of Canadian dollars, except for share and per share amounts]

 
                                                                                                                                                                                                    
   2020    2019  
   
Revenues   199,519    47,461  
Cost of goods sold   117,829    20,543  
  Gross margin    81,690    26,918  
   
  Expenses    
Selling and marketing   35,585    7,789  
General and administrative   38,845    24,460  
Research and development   11,725    3,913  
Amortization of intangibles   25,535    3,413  
Impairment of intangibles   656    4,226  
  Operating loss    (30,656    )   (16,883 )
   
Interest income on financial instruments measured at amortized cost   (9,112    )   (18,780 )
Other interest income   (5,210    )   (4,762 )
Interest expense   3,398    370  
Other income   (169    )   (2,195 )
Net gain on financial instruments measured at fair value through profit or loss   (48,060    )   (20,714 )
Net (gain) loss on mandatory tender offer liability   (12,072    )   5,757  
Realized gain on sale of asset held for sale   (2,948    )   
Realized gain on automatic share purchase plan   (4,168    )   
Share of net income of associate     (906 )
Foreign exchange loss   14,156    1,389  
Loss on hyperinflation   1,444    176  
  Income before income taxes    32,085    22,782  
   
  Income tax    
Current   2,337    3,836  
Deferred   (2,012    )   913  
  Income tax (recovery) expense    325    4,749  
  Net income for the year    31,760    18,033  
   
  Attributable to:    
Shareholders of the Company   42,067    14,517  
Non-controlling interests   (10,307    )   3,516  
   
  Attributable to shareholders of the Company    
Basic earnings per share   0.32    0.10  
Diluted earnings per share   0.32    0.10  
   
  Weighted average number of common shares outstanding    
Basic   131,783,255    139,758,522  
Diluted   131,985,025    140,139,220  
 

 

 

  CONSOLIDATED STATEMENTS OF CASH FLOWS  
[In thousands of Canadian dollars]

 
                                                                                                                                                                                                                                                                                       
   2020    2019    
  OPERATING ACTIVITIES    
  Net income for the year    31,760    18,033  
Adjustments reconciling net income to operating cash flows:   
Deferred income tax   (2,012    )   913  
Share-based compensation expense   1,950    2,137  
Depreciation and amortization   32,075    4,270  
Impairment on intangible assets   656    4,226  
Net gain on financial instruments   (48,060    )   (20,714 )
Net (gain) loss on mandatory tender offer liability   (12,072    )   5,757  
Realized gain on sale of asset held for sale   (2,948    )   
Realized gain on automatic share purchase plan   (4,168    )   
Interest Expense   3,398    370  
Unrealized foreign exchange loss   9,429    1,389  
Loss on hyperinflation   1,444    176  
Share of net income of associate     (906 )
Other adjustments   (81    )   (809 )
   11,371    14,842  
Changes in non-cash working capital and other items   (21,607    )   6,043  
Other receivable     (18,242 )
Dividends from associate     4,159  
Interest payments on bank loans   (1,969    )   (2,206 )
  Cash (outflow) inflow from operating activities    (12,205    )   4,596  
   
  INVESTING ACTIVITIES    
Acquisition of subsidiary, net of cash acquired   (170,855    )   (172,306 )
Purchase of marketable securities   (37,778    )   (223,507 )
Purchase of intangibles   (15,290    )   (2,839 )
Purchase of property and equipment   (5,378    )   (109 )
Issuance of loans receivables   (7,364    )   (20,046 )
Purchase of equity investments and derivatives   (397    )   (538 )
Settlement of forward foreign exchange contracts     (3,447 )
Investment in funds   (15,766    )   (20,175 )
Proceeds on sale of asset held for sale   77,000    
Proceeds on maturity of marketable securities   237,263    400,373  
Proceeds from repayments of loans receivable   7,803    8,540  
Proceeds from disposal of equity investments   2,987    4,104  
Proceeds from distribution of funds   29,128    18,090  
  Cash inflow (outflow) from investing activities    101.353    (11,860 )
   
  FINANCING ACTIVITIES    
Proceeds from exercise of stock options   595    
Proceeds from contributions to share purchase plan   231    230  
Proceeds from repayment of share purchase loans     425  
Proceeds from bank loans   24,581    
Repurchase of common shares through Normal Course Issuer Bid   (36,787    )   (54,838 )
Principal repayment of lease liabilities   (3,139    )   (716 )
Principal repayments on bank loans   (14,714    )   (7,896 )
  Cash outflow from financing activities    (29,233    )   (62,795 )
   
  Increase (decrease) in cash and cash equivalents during the year    59,916    (70,059 )
Cash and cash equivalents, beginning of the year   174,268    244,785  
Net foreign exchange difference   (4,592    )   (458 )
  Cash and cash equivalents, end of the year    229,592    174,268  
   
Cash and cash equivalents   229,592    174,268  
Short-term marketable securities   147,316    235,045  
Long-term marketable securities   15,317    126,869  
  Total cash, cash equivalents and marketable securities    392,225    536,182  
 

  Primary Logo 

 

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×